• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[一种预测根治性肾切除术后总生存期的新型列线图的建立与验证]

[Establishment and validation of a novel nomogram to predict overall survival after radical nephrectomy].

作者信息

Xiong L B, Zou X P, Ning K, Luo X, Peng Y L, Zhou Z H, Wang J, Li Z, Yu C P, Dong P, Guo S J, Han H, Zhou F J, Zhang Z L

机构信息

Department of Urology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.

出版信息

Zhonghua Zhong Liu Za Zhi. 2023 Aug 23;45(8):681-689. doi: 10.3760/cma.j.cn112152-20221027-00722.

DOI:10.3760/cma.j.cn112152-20221027-00722
PMID:37580273
Abstract

To establish a nomogram prognostic model for predicting the 5-, 10-, and 15-year overall survival (OS) of non-metastatic renal cell carcinoma patients managed with radical nephrectomy (RN), compare the modelled results with the results of pure pathologic staging, the Karakiewicz nomogram and the Mayo Clinic Stage, Size, Grade, and Necrosis (SSIGN) score commonly used in foreign countries, and stratify the patients into different prognostic risk subgroups. A total of 1 246 non-metastatic renal cell carcinoma patients managed with RN in Sun Yat-sen University Cancer Center (SYSUCC) from 1999 to 2020 were retrospectively analyzed. Multivariate Cox regression analysis was used to screen the variables that influence the prognosis for nomogram establishment, and the bootstrap random sampling was used for internal validation. The time-receiver operating characteristic curve (ROC), the calibration curve and the clinical decision curve analysis (DCA) were applied to evaluate the nomogram. The prediction efficacy of the nomogram and that of the pure pathologic staging, the Karakiewicz nomogram and the SSIGN score was compared through the area under the curve (AUC). Finally, patients were stratified into different risk subgroups according to our nomogram scores. A total of 1 246 patients managed with RN were enrolled in this study. Multivariate Cox regression analysis showed that age, smoking history, pathological nuclear grade, sarcomatoid differentiation, tumor necrosis and pathological T and N stages were independent prognostic factors for RN patients (all <0.05). A nomogram model named SYSUCC based on these factors was built to predict the 5-, 10-, and 15-year survival rate of the participating patients. In the bootstrap random sampling with 1 000 iterations, all these factors occurred for more than 800 times as independent predictors. The Harrell's concordance index (C-index) of SYSUCC was higher compared with pure pathological staging [0.770 (95% 0.716-0.823) vs 0.674 (95% 0.621-0.728)]. The calibration curve showed that the survival rate as predicted by the SYSUCC model simulated the actual rate, while the clinical DCA showed that the SYSUCC nomogram has a benefit in certain probability ranges. In the ROC analysis that included 857 patients with detailed pathological nuclear stages, the nomogram had a larger AUC (5-/10-year AUC: 0.823/0.804) and better discriminating ability than pure pathological staging (5-/10-year AUC: 0.701/0.658), Karakiewicz nomogram (5-/10-year AUC: 0.772/0.734) and SSIGN score (5-/10-year AUC: 0.792/0.750) in predicting the 5-/10-year OS of RN patients (all <0.05). In addition, the AUC of the SYSUCC nomogram for predicting the 15-year OS (0.820) was larger than that of the SSIGN score (0.709), and there was no statistical difference (<0.05) between the SYSUCC nomogram, pure pathological staging (0.773) and the Karakiewicz nomogram (0.826). The calibration curve was close to the standard curve, which indicated that the model has good predictive performance. Finally, patients were stratified into low-, intermediate-, and high-risk subgroups (738, 379 and 129, respectively) according to the SYSUCC nomogram scores, among whom patients in intermediate- and high-risk subgroups had a worse OS than patients in the low-risk subgroup (intermediate-risk group vs. low-risk group: =4.33, 95% 3.22-5.81, <0.001; high-risk group vs low-risk group: =11.95, 95% 8.29-17.24, <0.001), and the high-risk subgroup had a worse OS than the intermediate-risk group (=2.63, 95% : 1.88-3.68, <0.001). Age, smoking history, pathological nuclear grade, sarcomatoid differentiation, tumor necrosis and pathological stage were independent prognostic factors for non-metastasis renal cell carcinoma patients after RN. The SYSUCC nomogram based on these independent prognostic factors can better predict the 5-, 10-, and 15-year OS than pure pathological staging, the Karakiewicz nomogram and the SSIGN score of patients after RN. In addition, the SYSUCC nomogram has good discrimination, agreement, risk stratification and clinical application potential.

摘要

建立列线图预后模型以预测接受根治性肾切除术(RN)的非转移性肾细胞癌患者的5年、10年和15年总生存期(OS),将建模结果与国外常用的单纯病理分期、Karakiewicz列线图以及梅奥诊所分期、大小、分级和坏死(SSIGN)评分的结果进行比较,并将患者分层为不同的预后风险亚组。回顾性分析了1999年至2020年在中山大学肿瘤防治中心(SYSUCC)接受RN治疗的1246例非转移性肾细胞癌患者。采用多因素Cox回归分析筛选影响列线图建立的预后变量,并采用自抽样随机抽样进行内部验证。应用时间-受试者工作特征曲线(ROC)、校准曲线和临床决策曲线分析(DCA)对列线图进行评估。通过曲线下面积(AUC)比较列线图与单纯病理分期、Karakiewicz列线图和SSIGN评分的预测效能。最后,根据我们的列线图评分将患者分层为不同的风险亚组。本研究共纳入1246例接受RN治疗的患者。多因素Cox回归分析显示,年龄、吸烟史、病理核分级、肉瘤样分化、肿瘤坏死以及病理T和N分期是RN患者的独立预后因素(均<0.05)。基于这些因素构建了一个名为SYSUCC的列线图模型,以预测参与患者的5年、10年和15年生存率。在1000次迭代的自抽样随机抽样中,所有这些因素作为独立预测因子出现超过800次。SYSUCC的Harrell一致性指数(C指数)高于单纯病理分期[0.770(95% 0.716 - 0.823)对0.674(95% 0.621 - 0.728)]。校准曲线显示,SYSUCC模型预测的生存率模拟了实际生存率,而临床DCA显示SYSUCC列线图在特定概率范围内具有优势。在纳入857例有详细病理核分期患者的ROC分析中,列线图在预测RN患者的5年/10年OS方面比单纯病理分期(5年/10年AUC:0.701/0.658)、Karakiewicz列线图(5年/10年AUC:0.772/0.734)和SSIGN评分(5年/10年AUC:0.792/0.750)具有更大的AUC(5年/10年AUC:0.823/0.804)和更好的区分能力(均<0.05)。此外,SYSUCC列线图预测15年OS的AUC(0.820)大于SSIGN评分(0.709),SYSUCC列线图、单纯病理分期(0.773)和Karakiewicz列线图(0.826)之间无统计学差异(<0.05)。校准曲线接近标准曲线,表明该模型具有良好的预测性能。最后,根据SYSUCC列线图评分将患者分层为低、中、高风险亚组(分别为738例、379例和129例),其中中、高风险亚组患者的OS比低风险亚组患者差(中风险组与低风险组:=4.33,95% 3.22 - 5.81,<0.001;高风险组与低风险组:=11.95,95% 8.29 - 17.24,<0.001),且高风险亚组患者的OS比中风险组差(=2.63,95%:1.88 - 3.68,<0.001)。年龄、吸烟史、病理核分级、肉瘤样分化、肿瘤坏死和病理分期是RN术后非转移性肾细胞癌患者的独立预后因素。基于这些独立预后因素的SYSUCC列线图在预测RN术后患者的5年、10年和15年OS方面比单纯病理分期、Karakiewicz列线图和SSIGN评分表现更好。此外,SYSUCC列线图具有良好的区分度、一致性、风险分层和临床应用潜力。

相似文献

1
[Establishment and validation of a novel nomogram to predict overall survival after radical nephrectomy].[一种预测根治性肾切除术后总生存期的新型列线图的建立与验证]
Zhonghua Zhong Liu Za Zhi. 2023 Aug 23;45(8):681-689. doi: 10.3760/cma.j.cn112152-20221027-00722.
2
[Predicting the 3-year tumor-specific survival in patients with T non-metastatic renal cell carcinoma].[预测T期非转移性肾细胞癌患者的3年肿瘤特异性生存率]
Beijing Da Xue Xue Bao Yi Xue Ban. 2024 Aug 18;56(4):673-679. doi: 10.19723/j.issn.1671-167X.2024.04.021.
3
A novel nomogram and risk classification system predicting the overall survival of patients with papillary renal cell carcinoma after nephrectomy: A population-based study.一种基于人群的研究:预测肾细胞癌患者肾切除术后总生存的新型列线图和风险分类系统。
Front Public Health. 2022 Oct 5;10:989566. doi: 10.3389/fpubh.2022.989566. eCollection 2022.
4
Development and validation of a nomogram to predict overall survival for patients with metastatic renal cell carcinoma.开发和验证用于预测转移性肾细胞癌患者总生存期的列线图。
BMC Cancer. 2020 Nov 4;20(1):1066. doi: 10.1186/s12885-020-07586-7.
5
Application of the Stage, Size, Grade, and Necrosis (SSIGN) Score for Clear Cell Renal Cell Carcinoma in Contemporary Patients.当代患者中透明细胞肾细胞癌的分期、大小、分级及坏死(SSIGN)评分的应用
Eur Urol. 2017 Apr;71(4):665-673. doi: 10.1016/j.eururo.2016.05.034. Epub 2016 Jun 7.
6
[Establishment and validation of a nomogram to predict overall survival of patients with gastric neuroendocrine neoplasms].[建立和验证预测胃神经内分泌肿瘤患者总生存期的列线图]
Zhonghua Wei Chang Wai Ke Za Zhi. 2021 Oct 25;24(10):883-888. doi: 10.3760/cma.j.cn.441530-20210716-00283.
7
Prognostic nomograms and Aggtrmmns scoring system for predicting overall survival and cancer-specific survival of patients with kidney cancer.用于预测肾癌患者总生存期和癌症特异性生存期的预后列线图及Aggtrmmns评分系统。 需注意,原文中的“Aggtrmmns”可能有误,不太明确其准确含义。
Cancer Med. 2020 Apr;9(8):2710-2722. doi: 10.1002/cam4.2916. Epub 2020 Feb 22.
8
Development and validation of a nomogram to predict recurrence for clinical T1/2 clear cell renal cell carcinoma patients after nephrectomy.建立并验证一个列线图模型以预测 T1/T2 期肾透明细胞癌患者肾切除术后的复发风险。
BMC Surg. 2024 Jun 26;24(1):196. doi: 10.1186/s12893-024-02487-z.
9
External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.在一家欧洲中心,通过常规病理学方法对 Mayo 临床分期、大小、分级和坏死(SSIGN)评分在透明细胞肾细胞癌中的应用进行外部验证。
Eur Urol. 2010 Jan;57(1):102-9. doi: 10.1016/j.eururo.2008.11.033. Epub 2008 Nov 28.
10
A nomogram model based on the number of examined lymph nodes-related signature to predict prognosis and guide clinical therapy in gastric cancer.基于检查淋巴结数量相关特征的列线图模型预测胃癌的预后并指导临床治疗。
Front Immunol. 2022 Nov 2;13:947802. doi: 10.3389/fimmu.2022.947802. eCollection 2022.